JP2019517511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517511A5 JP2019517511A5 JP2018563090A JP2018563090A JP2019517511A5 JP 2019517511 A5 JP2019517511 A5 JP 2019517511A5 JP 2018563090 A JP2018563090 A JP 2018563090A JP 2018563090 A JP2018563090 A JP 2018563090A JP 2019517511 A5 JP2019517511 A5 JP 2019517511A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- tumor
- months
- expression pattern
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 22
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 15
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 15
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 claims 6
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 claims 6
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022146466A JP2022188071A (ja) | 2016-06-03 | 2022-09-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
| JP2025022545A JP2025081454A (ja) | 2016-06-03 | 2025-02-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345658P | 2016-06-03 | 2016-06-03 | |
| US62/345,658 | 2016-06-03 | ||
| PCT/US2017/035798 WO2017210624A1 (en) | 2016-06-03 | 2017-06-02 | Anti-pd-1 antibody for use in a method of treating a tumor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022146466A Division JP2022188071A (ja) | 2016-06-03 | 2022-09-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517511A JP2019517511A (ja) | 2019-06-24 |
| JP2019517511A5 true JP2019517511A5 (OSRAM) | 2020-07-09 |
Family
ID=59067919
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563090A Pending JP2019517511A (ja) | 2016-06-03 | 2017-06-02 | 腫瘍を処置する方法において使用するための抗ｐｄ−１抗体 |
| JP2022146466A Pending JP2022188071A (ja) | 2016-06-03 | 2022-09-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
| JP2025022545A Pending JP2025081454A (ja) | 2016-06-03 | 2025-02-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022146466A Pending JP2022188071A (ja) | 2016-06-03 | 2022-09-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
| JP2025022545A Pending JP2025081454A (ja) | 2016-06-03 | 2025-02-14 | 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20200325226A1 (OSRAM) |
| EP (1) | EP3464369A1 (OSRAM) |
| JP (3) | JP2019517511A (OSRAM) |
| KR (3) | KR20190015408A (OSRAM) |
| CN (1) | CN109476753A (OSRAM) |
| WO (1) | WO2017210624A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018000768A2 (pt) | 2015-07-13 | 2018-09-25 | Cytomx Therapeutics Inc | anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos |
| AU2016305697B2 (en) | 2015-08-11 | 2023-02-02 | WuXi Biologics Ireland Limited | Novel anti-PD-1 antibodies |
| PT3377534T (pt) | 2015-11-18 | 2025-07-10 | Bristol Myers Squibb Co | Tratamento do cancro do pulmão utilizando uma combinação de um anticorpo anti-pd-1 e de um anticorpo anti-ctla-4 |
| US11566073B2 (en) | 2017-06-01 | 2023-01-31 | Bristol-Myers Squibb Company | Methods of treating a tumor using an anti-PD-1 antibody |
| US20200405806A1 (en) * | 2018-02-08 | 2020-12-31 | Bristol-Myers Squibb Company | Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors |
| BR112020016331A8 (pt) | 2018-02-13 | 2023-02-07 | Merck Sharp & Dohme | Métodos para tratar câncer com anticorpos anti-pd-1 |
| MA51844A (fr) * | 2018-02-13 | 2021-05-19 | Merck Sharp & Dohme | Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4 |
| WO2019207030A1 (en) * | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer |
| WO2020139941A1 (en) * | 2018-12-27 | 2020-07-02 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Treatment of stk11-loss cancers |
| EP3946625A1 (en) * | 2019-03-28 | 2022-02-09 | Bristol-Myers Squibb Company | Methods of treating tumor |
| BR112022003163A2 (pt) * | 2019-08-19 | 2022-05-17 | Pandion Operations Inc | Imunotolerância alvejada com um agonista de pd-1 |
| EP4387104A1 (en) | 2022-12-13 | 2024-06-19 | LX Semicon Co., Ltd. | Analog-to-digital converter and semiconductor device having the same |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1210428T3 (en) | 1999-08-23 | 2015-06-15 | Dana Farber Cancer Inst Inc | PD-1, a receptor for B7-4 AND USE THEREOF |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA023148B1 (ru) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| CN104961829B (zh) | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR102702287B1 (ko) | 2012-05-15 | 2024-09-04 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| EP2981821B2 (en) | 2013-04-02 | 2021-11-03 | Merck Sharp & Dohme Corp. | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| PT2992017T (pt) * | 2013-05-02 | 2021-01-29 | Anaptysbio Inc | Anticorpos dirigidos contra a morte programada 1 (pd-1) |
| HK1221964A1 (zh) | 2013-05-31 | 2017-06-16 | Sorrento Therapeutics, Inc. | 与pd-1结合的抗原结合蛋白 |
| RS63571B9 (sr) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva |
| PL3081576T3 (pl) | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3149042B1 (en) * | 2014-05-29 | 2019-08-28 | Spring Bioscience Corporation | Pd-l1 antibodies and uses thereof |
| SG10201807625PA (en) * | 2014-11-17 | 2018-10-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| WO2016149201A2 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
-
2017
- 2017-06-02 EP EP17730636.2A patent/EP3464369A1/en active Pending
- 2017-06-02 KR KR1020187038120A patent/KR20190015408A/ko not_active Ceased
- 2017-06-02 CN CN201780048321.0A patent/CN109476753A/zh active Pending
- 2017-06-02 US US16/306,380 patent/US20200325226A1/en not_active Abandoned
- 2017-06-02 KR KR1020257022183A patent/KR20250107295A/ko active Pending
- 2017-06-02 JP JP2018563090A patent/JP2019517511A/ja active Pending
- 2017-06-02 WO PCT/US2017/035798 patent/WO2017210624A1/en not_active Ceased
- 2017-06-02 KR KR1020237026427A patent/KR20230118713A/ko not_active Ceased
-
2022
- 2022-03-21 US US17/699,949 patent/US20220315657A1/en not_active Abandoned
- 2022-09-14 JP JP2022146466A patent/JP2022188071A/ja active Pending
-
2025
- 2025-02-14 JP JP2025022545A patent/JP2025081454A/ja active Pending
- 2025-05-20 US US19/213,805 patent/US20250382368A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517511A5 (OSRAM) | ||
| Stuurman et al. | Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement | |
| Zhao et al. | Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo | |
| Laderian et al. | CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib | |
| Dhillon | Palbociclib: first global approval | |
| Jhaveri et al. | Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions | |
| Murphy et al. | The role of CDK4/6 inhibition in breast cancer | |
| Alzoubi et al. | Stimulation of suicidal erythrocyte death by artesunate | |
| JP2019517498A5 (OSRAM) | ||
| JP2019517504A5 (OSRAM) | ||
| JP2018508516A5 (OSRAM) | ||
| Conlin et al. | Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer | |
| Villanueva et al. | A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study | |
| JP2019517512A5 (OSRAM) | ||
| JP2019521087A5 (OSRAM) | ||
| RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
| JP2019517505A5 (OSRAM) | ||
| Hwang et al. | A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer | |
| JP2019536805A5 (OSRAM) | ||
| JP2019503365A5 (OSRAM) | ||
| JP2018512391A5 (OSRAM) | ||
| JP2019503387A5 (OSRAM) | ||
| JP2019530706A5 (OSRAM) | ||
| Novello et al. | A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer | |
| Lu et al. | Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial) |